Corrigendum: Cost-Effective, Safe, and Personalized Cell Therapy for Critical Limb Ischemia in Type 2 Diabetes Mellitus.
Soria-Juan B, Escacena N, Capilla-González V, Aguilera Y, Llanos L, Tejedo JR, Bedoya FJ, Juan V, De la Cuesta A, Ruiz-Salmerón R, Andreu E, Grochowicz L, Prósper F, Sánchez-Guijo F, Lozano FS, Miralles M, Del Río-Solá L, Castellanos G, Moraleda JM, Sackstein R, García-Arranz M, García-Olmo D, Martín F, Hmadcha A, Soria B; Collaborative Working Group “Noma Project Team”.
Soria-Juan B, et al. Among authors: lozano fs.
Front Immunol. 2020 Sep 2;11:2029. doi: 10.3389/fimmu.2020.02029. eCollection 2020.
Front Immunol. 2020.
PMID: 32983148
Free PMC article.